drugset / Trial / NCT05403333
Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II trial to explore the efficacy and safety of weekly utidelone in HER2-negative inoperable locally advanced or metastatic breast cancer.
Timeline
- Start
- 2022-06-10
- Primary completion
- 2023-03-09
- Completion
- 2025-03-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epothilone D | Small molecule | 65 mg/m2 | Intravenous |